T. Rowe Price Associates’s DexCom DXCM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $153M | Buy |
|
|||||
|
2025
Q1 | $102M | Sell |
|
|||||
|
2024
Q4 | $151M | Sell |
|
|||||
|
2024
Q3 | $216M | Sell |
|
|||||
|
2024
Q2 | $391M | Buy |
|
|||||
|
2024
Q1 | $409M | Sell |
|
|||||
|
2023
Q4 | $682M | Buy |
|
|||||
|
2023
Q3 | $312M | Sell |
|
|||||
|
2023
Q2 | $465M | Sell |
|
|||||
|
2023
Q1 | $449M | Sell |
|
|||||
|
2022
Q4 | $457M | Buy |
|
|||||
|
2022
Q3 | $321M | Sell |
|
|||||
|
2022
Q2 | $305M | Buy |
|
|||||
|
2022
Q1 | $499M | Buy |
|
|||||
|
2021
Q4 | $344M | Buy |
|
|||||
|
2021
Q3 | $333M | Buy |
|
|||||
|
2021
Q2 | $242M | Sell |
|
|||||
|
2021
Q1 | $496M | Sell |
|
|||||
|
2020
Q4 | $791M | Sell |
|
|||||
|
2020
Q3 | $1.28B | Sell |
|
|||||
|
2020
Q2 | $1.42B | Sell |
|
|||||
|
2020
Q1 | $1.3B | Buy |
|
|||||
|
2019
Q4 | $1B | Sell |
|
|||||
|
2019
Q3 | $938M | Buy |
|
|||||
|
2019
Q2 | $818M | Buy |
|
|||||
|
2019
Q1 | $141M | Buy |
|
|||||
|
2018
Q4 | $66.7M | Sell |
|
|||||
|
2018
Q3 | $644M | Sell |
|
|||||
|
2018
Q2 | $530M | Sell |
|
|||||
|
2018
Q1 | $662M | Sell |
|
|||||
|
2017
Q4 | $573M | Buy |
|
|||||
|
2017
Q3 | $220M | Buy |
|
|||||
|
2017
Q2 | $165M | Sell |
|
|||||
|
2017
Q1 | $317M | Sell |
|
|||||
|
2016
Q4 | $267M | Buy |
|
|||||
|
2016
Q3 | $271M | Sell |
|
|||||
|
2016
Q2 | $270M | Sell |
|
|||||
|
2016
Q1 | $289M | Sell |
|
|||||
|
2015
Q4 | $350M | Sell |
|
|||||
|
2015
Q3 | $383M | Sell |
|
|||||
|
2015
Q2 | $398M | Buy |
|
|||||
|
2015
Q1 | $294M | Buy |
|
|||||
|
2014
Q4 | $239M | Buy |
|
|||||
|
2014
Q3 | $174M | Buy |
|
|||||
|
2014
Q2 | $159M | Buy |
|
|||||
|
2014
Q1 | $116M | Buy |
|
|||||
|
2013
Q4 | $7.47M | Buy |
|
|||||
|
2013
Q3 | $534K | Sell |
|
|||||
|
2013
Q2 | $494K | Buy |
|